Celgene's need for speed behind $500m antibody alliance with Sutro
This article was originally published in Scrip
Executive Summary
Sutro Biopharma hopes to announce one or two more collaborations with Big Pharma or large biotech companies within the next 12 months that will be similar to the San Francisco-based company's $500 million-plus deal with Celgene to design and develop novel antibody-drug conjugates (ADCs) and bi-specific antibodies for two undisclosed targets, and to manufacture an antibody from Celgene's early-stage pipeline.